BOT 6.45% 33.0¢ botanix pharmaceuticals ltd

Bot Chart, page-10630

  1. 1,644 Posts.
    lightbulb Created with Sketch. 1050
    On the other thread it was posted that figures for Ecclock sales in Japan have been released (I think to investors and analysts only at this stage) and it is being interpreted by analysts as something like this:

    "Impact - These figures provide insight into the potential future sales of Sofpironium Bromide in the United States, underscoring the considerable market opportunity at hand. Based on our analysis, we estimate Kaken sold ~72,000 prescriptions in 2Q, or +287,000 prescriptions on an annualised basis (Figure 4).More so, when applied to our estimate of US pricing (US$540/month; net), this annualised 2Q prescription figure implies ~A$239 million of annual revenues in the United States (Figure 5).Additionally, this is based on Japanese prescription volumes, the United States has a population nearly 3x larger than Japan – which would suggest even larger potential prescription volumes and sales are possible. "
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
33.0¢
Change
0.020(6.45%)
Mkt cap ! $519.7M
Open High Low Value Volume
31.0¢ 33.5¢ 30.5¢ $2.848M 8.878M

Buyers (Bids)

No. Vol. Price($)
1 24615 32.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.0¢ 105525 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
33.0¢
  Change
0.020 ( 6.73 %)
Open High Low Volume
31.0¢ 33.5¢ 30.8¢ 3931977
Last updated 15.59pm 14/06/2024 ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.